Biotech

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this...

Smartphone-sized bioartificial kidney prototype passes key test

The Kidney Project successfully tests a prototype bioartificial kidney and wins KidneyX’s $650,000 Artificial Kidney Prize. The Kidney Project’s implantable bioartificial kidney, one that promises...

Shifting gear: startup aims to de-risk rejuvenation therapy

Shift Bioscience raising funding to develop safe cellular reprogramming therapies for rejuvenation. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the...

Latest news

Shifting gear: startup aims to de-risk rejuvenation therapy

Shift Bioscience raising funding to develop safe cellular reprogramming therapies for rejuvenation. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the...

Senolytic cocktail reduces aging-associated disc degeneration

Senolytic drug therapies that target aging cells early pave the way to easing back pain. New findings, reported in Nature Communications, show how a novel...

Bezos billions fund new antiaging biotech start-up

Longevity steps centre-stage as Jeff Bezos and Yuri Milner launch new antiaging venture Altos Labs. Reprogramming tech is hot news right now; companies pushing the...

ARDD 2021 wraps up

ARDD 2021: Biological age from wearables, ripple effects on hallmarks of aging and linking NR to treatment of orphan disease. The final day of last...

Novel biotech will provide the best solution to age-related disease

ARDD 2021: DNA repair, mitochondrial enhancement, gene editing, and how a new era for longevity will help us beat age-related disease. After three great days...

Focus on frailty over aging

ARDD 2021: Novartis research scientist reveals shift towards targeting frailty, Insilico announces partnership with Gray Matter, aging clocks and much more. Yesterday at the 8th...

Longevity industry “taking shape”

ARDD 2021 kicks off: sessions to cover longevity topics from AI and senolytics to mitochondria and stem cell rejuvenation. Following yesterday’s workshops, ARDD 2021 really...

The need to educate in longevity

Lots to learn about longevity at ARDD 2021: from pharma and startups to physicians and high schoolers. This week, we’ll be bringing you a wealth...

Drug discovery secrets of the animal kingdom

Fauna CEO: humans have forgotten to learn from nature – animal biology and genetics may hold the key to drug discovery and human longevity. Whether...

New drug molecules could prevent skin aging caused by the sun

Two new molecules that generate minute amounts of the gas hydrogen sulfide have been found to prevent skin from aging after being exposed to...

Gene therapy uses SIRT6 variant found in centenarians

Genflow developing SIRT6 gene therapy “out of frustration with the nine hallmarks of aging”. British biotech startup Genflow Biosciences is on a mission to develop...

Growing the longevity startup wave through community

From connecting like-minded people to mentors illuminating the path to startup, the On Deck Longevity Biotech Fellowship is determined to foster longevity innovation. Just a...

CohBar announces positive human data from obesity study

Positive topline results from the Phase 1a/1b study of CB4211 under development for non-alcoholic steatohepatitis and obesity announced. CohBar, a California-based clinical stage biotechnology company...

Most popular

Nerve regeneration tech targets Alzheimer’s and Nasdaq

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve regeneration technology, Canadian biotech NervGen...

Insulin – predictor of longevity

Body weight stands for far more than simple aesthetics – it is key for longevity. From a single cell to a fully functioning human adult,...

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Senescence field has “completely exploded”

Aubrey de Grey expects senescence-targeting sector will see Phase 3 trials within “a couple of years”. As one of the hallmarks of aging, cellular senescence...

You might also like

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

SENS spin-out Underdog closes $10m financing round

Underdog Pharmaceuticals, a key investment of rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Michael Greve’s Kizoo Technology Capital Group led the...
Nutriop